|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Adenocarcinoma of the Prostate | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Adenocarcinoma | |||||
| Prostatic Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Carcinoma | |||||
| Genital Diseases, Male | |||||
| Genital Neoplasms, Male | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Prostatic Diseases | |||||
| Urogenital Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| Bicalutamide (Casodex) | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Bicalutamide | |||||
| 6 | More general drug interventions related to this trial | ||||
| Androgen Antagonists | |||||
| Antineoplastic Agents | |||||
| Hormone Antagonists | |||||
| Hormones, Hormone Substitutes, and Hormone Antagonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| AstraZeneca | |||||